CTOs on the Move

Kailos Genetics

www.praxiscanhelp.com

 
Kailos Genetics, the maker of Praxis, provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying risks to common medications. Praxis is an easily accessible form of personalized medicine catered to your lifestyle.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

SAIC-Frederick

SAIC-Frederick is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lipomics Technologies

Lipomics Technologies is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Biomedical

United Biomedical, Inc. (UBI) is an international bio/pharmaceutical firm with cutting edge technology utilizing reverse genomics and synthetic peptide chemistry, coupled with traditional pharmaceutical and therapeutic delivery systems. The company has

Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.

Tessera Therapeutics

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.